- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03467386
Ytimen ja imusolmukkeiden kokonaissäteilytys ennen luovuttajan siirtoa ja syklofosfamidi hoidettaessa potilaita, joilla on akuutti myelooinen leukemia
Pilottitutkimus kokonaisytimen/lymfoidin säteilytyksen (TMLI) hoidosta ennen allogeenistä hematopoieettista kantasolusiirtoa (HCT) ja sen jälkeen transplantaation jälkeistä syklofosfamidiin perustuvaa siirrännäis-isäntätaudin ennaltaehkäisyä akuutin myelogeenisen leukemian hoidossa täydellisessä remissiossa
This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone marrow and blood, instead of applying radiation to the whole body. Giving total bone marrow and lymphoid irradiation before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving total bone marrow and lymphoid irradiation before donor transplant and cyclophosphamide after transplant may work better at treating acute myeloid leukemia.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVE:
I. To evaluate the safety/feasibility of combining a total marrow and lymphoid irradiation (TMLI) transplant conditioning regimen with a post-transplant high dose cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis strategy, through the assessment of: adverse events: type, frequency, severity, attribution, time course, duration and complications: including acute GvHD, infection and delayed neutrophil/platelet engraftment.
SECONDARY OBJECTIVES:
I. To estimate the cumulative incidence (CI) of acute GvHD at 100 days post allogeneic hematopoietic cell transplantation (alloHCT).
II. To estimate the CI of chronic GvHD at 6 months, 1- and 2-years post alloHCT.
III. To estimate GVHD-free relapse-free survival (GRFS) at 1- and 2-years post alloHCT.
IV. To describe the kinetics of immune reconstitution and T cell repertoire in the first year post alloHCT.
V. To estimate overall survival (OS), relapse-free survival (RFS) and CI of relapse, and non-relapse mortality (NRM) at 100 days, 1- and 2-years post alloHCT.
VI. To characterize quality of life using 36-Item Short Form Health Survey (SF-36), Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and M. D. Anderson Symptom Inventory (MDASI) or Pediatric Quality of Life Inventory (PedsQL) at 100 days, 6 months, 1- and 2-years post alloHCT.
VII. To assess bone marrow cellularity from bone marrow samples. VIII. To assess the clonogenic potential of cells from bone marrow samples. IX. To assess stromal damage from bone marrow samples. X. To evaluate cytokines and oxidative stress markers.
OUTLINE: This is a dose-escalation study of TMLI.
Patients undergo TMLI twice daily (BID) on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide intravenously (IV) over 2 hours on days 3 and 4, tacrolimus given by continuous intravenous infusion (CIV) on days 5-90, and filgrastim beginning on day 5 until absolute neutrophil count (ANC) is at least 1,500/mm^3 for 3 consecutive days.
After completion of study treatment, patients are followed for up to 24 months.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Duarte, California, Yhdysvallat, 91010
- City of Hope Medical Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- This study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)
- Karnofsky performance status (KPS) >= 70%
- The effects of radiation on the developing fetus are known to be teratogenic; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
- Patients with acute myelogenous leukemia (AML) who are in first or second complete remission
- All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques; (red cell exchange or plasma exchange)
- A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
- Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 70 ml/min as calculated by the Cockcroft-Gault formula
- A bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease
- Patients should also have a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
- Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value
- All subjects must have the ability to understand and the willingness to sign a written informed consent; signed informed consent form approved by the Institutional Review Board (IRB) is required; the patient, family member, and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting, all pertinent information with respect to risks and benefits to the donor and recipient will be presented; alternative treatment modalities will be discussed
- The time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days
- Prior therapy with etoposide and cyclophosphamide is allowed
- DONOR: donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)
Exclusion Criteria:
- Patients should not have any uncontrolled illness including ongoing or active or poorly controlled infection
- Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; maintenance therapy with Food and Drug Administration (FDA)-approved targeted therapies (e.g. tyrosine kinase inhibitors for Philadelphia chromosome [Ph] positive [+] acute lymphoblastic leukemia [ALL], and FLT inhibitors for FLT3+ patients) will be allowed after day 60 disease assessment
- Prior radiation therapy that would exclude the use of TMLI
- Relapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously
- Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
- Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
- Patients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollment
- Patients with other active malignancies are ineligible for this study, other than localized malignancies
- Patients that are pregnant or breastfeeding
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to, infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Treatment (TMLI, cyclophosphamide)
Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days. |
Correlative studies Ancillary studies
Muut nimet:
Given IV
Muut nimet:
Ancillary studies Undergo alloHCT
Muut nimet:
Administer according to City of Hope standard operating procedures
Muut nimet:
Given CIV
Muut nimet:
Undergo TMLI |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
1a. Incidence of adverse events
Aikaikkuna: Up to 24 months
|
Assessed using Bearman Scale Regimen-Related Toxicity scale. Scale range: Grade 0-4 (increasing grade reflects increasing severity), where Grade 0-none/did not experience and Grade 4=death. |
Up to 24 months
|
|
1b. Incidence of adverse events
Aikaikkuna: Up to 24 months
|
Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale. Scale range: Grade 1-5 (increasing grade reflects increasing severity), where Grade 1 reflects a more milder form of the adverse event and Grade 5=death. |
Up to 24 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Aika neutrofiilien ja verihiutaleiden palautumiseen/siirrännäiseen
Aikaikkuna: Päivästä 0 toipumiseen tai istuttamisen epäonnistumisen ilmoittamiseen, arvioituna 24 kuukauden ajan
|
Päivästä 0 toipumiseen tai istuttamisen epäonnistumisen ilmoittamiseen, arvioituna 24 kuukauden ajan
|
|
|
Luuytimen jäännösvaurion arviointi
Aikaikkuna: Jopa 24 kuukautta
|
Jopa 24 kuukautta
|
|
|
Sytokiinit
Aikaikkuna: Jopa 24 kuukautta
|
Jopa 24 kuukautta
|
|
|
Oksidatiivisen stressin merkkiaineet
Aikaikkuna: Jopa 24 kuukautta
|
Jopa 24 kuukautta
|
|
|
Acute graft versus host disease (GvHD)
Aikaikkuna: Day 0 to 100 (120) days post-transplant
|
Graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999). |
Day 0 to 100 (120) days post-transplant
|
|
Chronic GVHD
Aikaikkuna: From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
|
The first day of chronic GvHD onset will be used to calculate cumulative incidence curves, with relapse/death prior to onset considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999). |
From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
|
|
GvHD-free/relapse-free survival (GRFS)
Aikaikkuna: From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
|
Will be calculated using the Kaplan-Meier method. |
From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
|
|
Levels of immune cells
Aikaikkuna: Up to 24 months
|
Will be measured by flow cytometry for cell subsets: a. T-cells. |
Up to 24 months
|
|
Levels of immune cells
Aikaikkuna: Up to 24 months
|
Will be measured by flow cytometry for cell subsets: b. B-cells. |
Up to 24 months
|
|
Levels of immune cells
Aikaikkuna: Up to 24 months
|
Will be measured by flow cytometry for cell subsets: c. natural killer (NK) cells. |
Up to 24 months
|
|
Levels of immune cells
Aikaikkuna: Up to 24 months
|
Will be measured by flow cytometry for cell subsets: d. regulatory T cells (T-regs). |
Up to 24 months
|
|
Overall survival
Aikaikkuna: From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
|
Will be calculated using the Kaplan-Meier method. |
From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
|
|
Relapse-free survival
Aikaikkuna: From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
|
Will be calculated using the Kaplan-Meier method. |
From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
|
|
Relapse
Aikaikkuna: From start of therapy, assessed up to 24 months
|
Will be calculated using the competing risk method as described by Gooley et al. (1999). |
From start of therapy, assessed up to 24 months
|
|
Non-relapse mortality (NRM)
Aikaikkuna: From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
|
The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. Will be calculated using the Kaplan-Meier method and the competing risk method as described by Gooley et al. (1999). |
From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
|
|
Quality of life -Questionnaire
Aikaikkuna: Up to 24 months
|
Assessed using a. 36-Item Short Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are:
|
Up to 24 months
|
|
Quality of life-Function Assessment
Aikaikkuna: Up to 24 months
|
Assessed using b. Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). (FACT-BMT) is a 47-item, valid and reliable measure of five dimensions of quality of life in bone marrow transplant patients. The dimensions collected and assessed are:
|
Up to 24 months
|
|
Quality of life -Symptom Inventory
Aikaikkuna: Up to 24 months
|
Assessed using c. M. D. Anderson Symptom Inventory (MDASI). MDASI is a multi-symptom patient-reported outcome (PRO) measure for clinical and research use. Use the MDASI to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. The following parameters will be reported:
|
Up to 24 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Anthony S Stein, City of Hope Medical Center
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat
- Neoplasmat histologisen tyypin mukaan
- Hematologiset sairaudet
- Leukemia, myeloidi
- Leukemia
- Hemic- ja imusuutteet
- Leukemia, myelooinen, akuutti
- Peptidit
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Orgaaniset kemikaalit
- Terapeuttiset lääkkeet
- Kirurgiset toimenpiteet, operatiivinen
- Hiilivety
- Biologiset tekijät
- Hiilihydraatit
- Siirto
- Makrolidit
- Laktotonit
- Fosforamidi -sinapit
- Typpisinappiyhdisteet
- Sinappiyhdisteet
- Hiilivety, halogenoitu
- Fosforamidit
- Organofosforiyhdisteet
- Solunväliset signalointipeptidit ja proteiinit
- Glykoproteiinit
- Glykoconjugates
- Solunsiirto
- Solu- ja kudospohjainen terapia
- Biologinen terapia
- Pesäkkeitä stimuloivat tekijät
- Hematopoieettiset solujen kasvutekijät
- Sytokiinit
- Syklofosfamidi
- Takrolimuusi
- Kantasolujen siirto
- Granulosyyttipesäkkeitä stimuloiva tekijä
- Filgrastimi
Muut tutkimustunnusnumerot
- 17423
- 17423 (Muu tunniste: City of Hope Comprehensive Cancer Center)
- NCI-2018-00177 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .